Ivabradine Shows Promise as Tx for Hyperadrenergic POTS

Further study needed in other POTS subtypes In patients with hyperadrenergic postural orthostatic tachycardia syndrome (POTS), one month of treatment with ivabradine brought about significant improvements in several parameters, including heart rate, quality of life (QOL), and plasma norepinephrine (NE) levels, according to results from a recent study published in the Journal of the American

POTS Treatment: Scientifically & Medically Proven • MyHeart

PDF) Ivabradine in Postural Orthostatic Tachycardia Syndrome: A

PDF) Ivabradine in Postural Orthostatic Tachycardia Syndrome: A

PDF) Age-dependent modulation of xenobiotic metabolism in primary

Karsten HEUSSER, Senior Physician Scientist

POTS Treatment: Scientifically & Medically Proven • MyHeart

PDF) Ivabradine in Postural Orthostatic Tachycardia Syndrome: A

Randomized Trial of Ivabradine in Patients With Hyperadrenergic

Ivabradine in children with postural orthostatic tachycardia

Randomized Trial of Ivabradine in Patients With Hyperadrenergic

Ivabradine effects on COVID-19-associated postural orthostatic

Ivabradine in children with postural orthostatic tachycardia

PDF) Ivabradine in Postural Orthostatic Tachycardia Syndrome: A

PDF) Age-dependent modulation of xenobiotic metabolism in primary